US Equities Analysis

A — Agilent Technologies

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 23.71%
Profit Margins 19.55%
Return on Equity 21.33%
Return on Assets 8.61%
Free Float 0.28B
Dividend Yield 0.75%
Short Int % Utilisation 2.1%

2.2 Growth

Metric Value
Revenue Growth 10.0%
Free Cash Flow 0.93B
EBITDA 19.31 (Ratio)
Enterprise Value 38.91B
EV/Revenue 5.38
EV/EBITDA 19.31

Revenue growth of 10.0% indicates steady, moderate expansion.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.)* 32.57%
Risk / Std Dev (Ann.)* 32.89%
1-Year Price Return* 25.61%

Latest Market Data (as of 2026-08-14, US Eastern time):

Metric Value
Last Price $148.53
52-Week Range $108.35 – $160.27
Observation Count 251 trading days

The return and risk statistics use daily adjusted closes from the retrieved one-year series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating input Value
Revenue $6.95B
Prior annual revenue $6.51B
EBIT $1.55B
Tax rate 9.20%
NOPAT = EBIT × (1 − tax rate) $1.40B
Forecast start-growth basis 6.73%
Forecast policy latest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building block Value
NOPAT $1.40B
Add: depreciation & amortisation $288.00M
Less: capital expenditure -$407.00M
Less/(add): working-capital cash-flow movement -$131.00M
Current unlevered FCFF $1.15B

Explicit FCFF forecast

Forecast year Revenue growth NOPAT D&A Capex Change in NWC FCFF Present value
1 6.73% $1.50B $307.38M -$434.38M -$139.81M $1.23B $1.17B
2 5.67% $1.58B $324.81M -$425.47M -$147.74M $1.34B $1.14B
3 4.61% $1.66B $339.80M -$410.00M -$154.56M $1.43B $1.11B
4 3.56% $1.72B $351.88M -$388.23M -$160.06M $1.52B $1.06B
5 2.50% $1.76B $360.68M -$360.68M -$164.06M $1.60B $1.00B

Step 3 — Determine the Discount Rate (WACC)

WACC input Value
Risk-free rate 4.71%
Equity risk premium assumption 5.50%
Beta 1.23
Cost of equity 11.47%
Pre-tax cost of debt 3.32%
WACC 10.84%
WACC validation within standard range

Step 4 — Estimate Terminal Value

Terminal-value input Value
Perpetuity growth rate 2.50%
Terminal value $19.59B
Implied terminal EV / EBITDA 8.53x
Terminal value as % of enterprise value 68.10%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value component Value
Present value of explicit FCFF $5.49B
Present value of terminal value $11.71B
Indicated enterprise value $17.20B
Discounting convention mid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridge Value
Indicated enterprise value $17.20B
Less: gross interest-bearing debt $3.35B
Add: cash and equivalents $1.79B
Add: affiliate investments $0.00
Less: minority interests $0.00
Indicated common equity value $15.63B

Step 7 — Calculate Indicative Value Per Share

Per-share output Value
Shares used 285,000,000.00
Share-count basis reported diluted weighted-average shares
Current market price $148.26
DCF indicative value per share $54.85
Indicative value vs. market price -63.01%

Model Integrity Checks

Check Result
Perpetuity growth is below the risk-free rate pass
Perpetuity growth is below WACC pass
WACC is within the configured operating-company range pass
Terminal-year FCFF is positive pass
Terminal capex converges to D&A pass
Terminal-value concentration within review band
Implied price differs from spot by more than 30% review required

2.6 Investor-Style Research Screen

Educational screen Result
Buffett-inspired cash-quality checks 3/4 evidenced checks
Lynch-inspired balance-and-growth checks 4/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:20:16.974099 UTC; latest reported fiscal period: 2025-10-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

us-equity stock equity a health-care life-sciences-tools--services nasdaq